Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Provides Biosite with Option on Troponin Variant Biomarker

NEW YORK (GenomeWeb News) – Compugen said today that it had discovered and experimentally verified a variant of the Troponin I biomarker, and that it has granted an option to Biosite to develop the biomarker for immunoassay diagnostic products.
Compugen said that the variant, CGEN-144, has been verified to be differentially expressed as serum protein in myocardial infarction patients compared to healthy individuals. The Israel-based firm said that the Troponin variant, for which it was granted a US patent, was predicted by its immunoassay biomarker computational discovery platform.
Under the pact with Biosite, Compugen will provide Biosite with existing proprietary data related to the molecule. Biosite will develop and select antibodies that bind to the molecule to determine assay sensitivity and specificity in various disease states and as an addition to the currently commercialized Troponin I test.
The alliance also provides Biosite with an option to obtain worldwide, royalty-bearing rights to commercialize an immunoassay diagnostic product based on CGEN-144.
Biosite, which had 2006 revenue of $309 million, derives roughly 80 percent of its sales from cardiovascular tests. Last year, the firm was acquired by Inverness Medical Innovations for approximately $1.72 billion, after Beckman Coulter pulled out of a bidding war.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.